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Severe aortic stenosis is common, affecting 2% to 4% of
adults older than 75 years of age (1). Although surgical valve
replacement is effective, operative mortality and morbidity
can be signiﬁcant, particularly in the elderly. The paradox is
that the population with the highest prevalence of aortic
valve disease often ﬁnds surgery a less than desirable option.
In 2007, the Conformité Européenne mark of approval
was granted to both the Edwards SAPIEN and Medtronic
CoreValve, with approval extended to many more trans-
catheter valves since then. There now exists a considerable
body of clinical, quality-of-life, and economic evidence from
both registries and randomized trials supporting a role for
transcatheter aortic valve replacement (TAVR) as an alter-
native to open surgery (2–6).See page 210The study of Mylotte et al. (7) in this issue of the Journal
provides useful insight into the complex dynamics that have
driven the rapid adoption of TAVR in Western Europe.
An illuminating picture has emerged from this examining
national registries, reimbursement databases, and commer-
cial market analysis. For Western Europe as a whole, TAVR
procedures have more than tripled in recent years, from
4,498 in 2009 to 14,599 in 2010, and to 18,372 in 2011,
with an average implantation rate of 40.9 per million
inhabitants. In 2011, Germany was responsible for a full 43%
of all procedures in Europe. France was a distant second at
13%, followed by Italy at 10%, and the United Kingdom
including Northern Ireland at 7%. Not surprisingly TAVR
adoption correlated with economic indexes such as health
care expenditure per capita, sources of health care funding,
and reimbursement strategies. Those countries with the
highest implantation rates per capita (Germany, Austria, and
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France, although also covering all costs, limited availability of
the procedure to a small number of centers. The United
Kingdom is notable in that the decision to fund TAVR was
constrained at the local level, where competition for funding
may be intense. Not unexpectedly, TAVR rates correlated
with national economic health, with the rates lowest in the
struggling economies of southern Europe.
Despite this exponential increase in TAVR rates, Mylotte
et al. (7) estimate that TAVR remains greatly underused in
Western Europe. For 2011, theTAVR “penetration rate” (the
rate of actual TAVR use relative to potential use) in Germany
and Switzerland was 36.2% and 34.5%, respectively,
suggesting that even in these countries with the highest
adoption, the procedure was underused. However, two-thirds
of the 11 nations studied had penetration rates <15%, with
Portugal ranking lowest at 3%.
Arguably these low estimates of European penetration are
based on a liberal interpretation of the indications for
TAVR. More conservative interpretations have led some to
argue that TAVR is only indicated in the <10% patients
who are clearly ineligible for open surgery for technical
reasons, concluding that TAVR is already overused in many
European countries (8). Less conservative commentators
might argue that considerable evidence documents steadily
improving outcomes and underappreciated beneﬁts in terms
of reduced morbidity and mortality, concluding that TAVR
is underused (9,10). Clearly the denominator for penetration
rates remains controversial.
In contrast to Europe, the U.S. Food and Drug Admin-
istration did not approve TAVR until 2011, even then only
approving a single early generation device with very limited
indications. Importantly, regulatory approval was linked to
funding approval. Although considerably delayed, U.S.
adoption also appears rapid. One recent commercial market
analysis estimates that the U.S. market is already w50%
penetrated (JP Morgan. Edwards Lifesciences. North
American Equity Research, 2013). Compared with the
estimates of Mylotte et al. (7), this surprisingly high estimate
assumes relatively conservative PARTNER 1A (high risk)
and 1B (inoperable) trial–based indications for TAVR. For
TAVR rates to increase dramatically would require increased
adoption in “inoperable” patients, some of whom might be
too ill to beneﬁt, or an increase in “off-label” use, something
that both regulatory and funding agencies oppose. The
ongoing PARTNER II and SURTAVI trials may provide
randomized evidence sufﬁcient to convince regulatory and
funding agencies to expand TAVR indications to include
patients at intermediate surgical risk. However, realistic
timelines suggest that these extended indications are unlikely
to be approved until 2016 at the earliest.
When discussing penetration rates, the elephant in the
room may be the high costs associated with TAVR. Even a
country with a strong economy might ﬁnd TAVR too costly
for individuals in whom conventional surgery or medical
management might be considered clinically and socially
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221acceptable. Analyses suggest that TAVR costs may be similar
to those of surgery in extreme surgical risk patients, but
greater than surgery in high-risk operable patients (11,12).
Many registries as well as the recently completed randomized
PARTNER II inoperable trial document that ongoing
improvements in equipment, technique, and patient selection
can be associated with reductions in complications and
morbidity, major determinants of procedure cost (4,9,10).
Streamlined programs with an abbreviated focused workup
and facilitated discharge in selected patients have proven
feasible. However, important reductions in the high cost of
TAVR may require reducing the high cost of transcatheter
valves themselves. Price competition is just now becoming
evident in some countries; newer valves are being introduced
to the market at marginally lower costs, and truly low cost
valves are just now beginning to appear in South America and
Asia. Perhaps as the cost differential between transcatheter
and surgical aortic valves decreases, at least some of the
resistance to greater penetration will fade.
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